Dr Reddy’s Laboratories said that it has launched Tetrabenazine tablets in the US markets.
The company has launched Tetrabenazine tablets, a therapeutic equivalent generic version of Xenazine in the United States market approved by the US Food and Drug Administration (USFDA).
According to IMS Health, the Xenazine brand and generic has US sales of approximately USD 322 million MAT for the 12 months ended November 2017.
Tetrabenazine tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112.
Xenazine is a registered trademark of Valeant Pharmaceuticals Luxembourg SARL.
Meanwhile, shares of the company were trading at Rs 2156.00 apiece, down 0.04 per cent from the previous close at 12:10 hours on BSE.